Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556252 | 1.00 | TYMP (0.45) | TYMPHPGDCTSKNT5EIMPDH2 | |
| SCHEMBL22594612 | 1.00 | TYMP (0.45) | TYMPHPGDCTSKNT5EIMPDH2 | |
| SCHEMBL22556249 | 1.00 | TYMP (0.45) | TYMPHPGDCTSKNT5EIMPDH2 | |
| SCHEMBL19814139 | 0.90 | TYMP (0.39) | TYMPHPGDNT5EIMPDH2ADORA3 | |
| SCHEMBL19820358 | 0.90 | TYMP (0.39) | TYMPHPGDNT5EIMPDH2ADORA3 | |
| SCHEMBL21401315 | 0.90 | TYMP (0.39) | TYMPHPGDNT5EIMPDH2ADORA3 | |
| SCHEMBL22585437 | 0.90 | TYMP (0.39) | TYMPHPGD | |
| SCHEMBL23827270 | 0.87 | TYMP (0.43) | TYMPHPGDCTSKNT5EIMPDH2 | |
| SCHEMBL23827268 | 0.87 | TYMP (0.43) | TYMPHPGDCTSKNT5EIMPDH2 | |
| SCHEMBL30140997 | 0.87 | TYMP (0.51) | TYMPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | TYMP 76/4885HPGD 1764/4885CTSK 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.